Soleus Capital Management L.P. Acquires Shares of 262,500 Replimune Group, Inc. (NASDAQ:REPL)

Soleus Capital Management L.P. acquired a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 262,500 shares of the company’s stock, valued at approximately $3,179,000. Soleus Capital Management L.P. owned approximately 0.38% of Replimune Group as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Two Sigma Investments LP boosted its stake in Replimune Group by 18.6% during the fourth quarter. Two Sigma Investments LP now owns 212,586 shares of the company’s stock valued at $2,574,000 after buying an additional 33,346 shares during the last quarter. Tang Capital Management LLC raised its holdings in shares of Replimune Group by 125.0% during the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock worth $32,697,000 after acquiring an additional 1,500,000 shares in the last quarter. RTW Investments LP boosted its position in shares of Replimune Group by 82.1% during the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company’s stock valued at $25,007,000 after acquiring an additional 931,223 shares during the last quarter. Redmile Group LLC increased its position in Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company’s stock worth $59,406,000 after purchasing an additional 124,344 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Replimune Group during the fourth quarter valued at $117,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Price Performance

REPL stock opened at $7.85 on Monday. The stock has a market cap of $604.57 million, a PE ratio of -2.56 and a beta of 0.68. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a 50-day moving average price of $8.95 and a 200 day moving average price of $11.32. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Analysts Set New Price Targets

REPL has been the subject of a number of recent research reports. HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. BMO Capital Markets lifted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. boosted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.